Clinical Trial Results Highlight Efficacy of TRU Technology

Wed, Oct 20 2021 11:53 am

NZX/ASX Announcement

20 October 2021

Clinical trial results highlight efficacy of TruScreen cancer screening technology

Key Highlights
• A new study, published in the European Journal of Obstetrics and Gynaecology and Reproductive Biology1, concludes that TruScreen’s cervical cancer screening technology meets or exceeds the effectiveness of alternative cervical cancer screening methods
• The study evaluated the efficacy of TruScreen in screening for cervical abnormalities, in a real world, primary cervical cancer screening setting in China
• The TruScreen screening device was found to be very effective at detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2+ or CIN3+).

TruScreen Group Limited (NZX/ASX: TRU) (‘TRU’ or ‘the Company’) is pleased to inform the market of a study conducted in China, the results of which indicate that TruScreen’s cervical cancer screening technology has demonstrated to be an effective alternative to cervical cytology.

TruScreen matches or outperforms cytology for cervical screening

A recently published study conducted in China has confirmed the efficacy of TruScreen’s cervical cancer screening devices versus human papillomavirus (HPV) testing, cytological testing using the ThinPrep cytology test (TCT). The study recruited 458 women aged between 25 and 65 years, who received cervical cancer screening using all three methods. The clinical performance of TruScreen, alone and in combination with HPV testing, was evaluated to detect cervical intraepithelial neoplasia grade 2 or worse (CIN2+ or CIN3+).

The study concluded that for detection of CIN2+, the sensitivity and specificity of TruScreen were 83.78% and 78.86%, respectively. The specificity of TruScreen was significantly higher than those of HPV testing (50.59%, P < 0.001) and TCT (55.58%, P < 0.001). In high-risk HPV-positive women, the specificity of HPV testing combined with TruScreen was significantly higher than that of HPV testing combined with TCT (50% vs 39.9%, P = 0.004). Importantly, the sensitivity of HPV testing combined with TruScreen was comparable to that of HPV testing combined with TCT (93.94% vs 87.88%, P = 0.625). Similar patterns were also observed for CIN3+, demonstrating that TruScreen could be an alternative method to cytology.

Key findings of the study are outlined in the table below. For CIN2+, TruScreen had specificity of 78.86%, significantly higher than both HPV testing and TCT (50.59% and 55.58% respectively). TruScreen’s sensitivity of 83.78% was comparable to HPV testing and once again significantly higher than TCT (89.19% and 55.58% respectively).

The PPV for TruScreen (25.83%) was significantly higher than those for HPV testing (13.69%) and TCT (12.62%). TruScreen’s NPV figure (98.22%) was similar to that of HPV testing (98.16%) and TCT (95.90%). Similar trends were apparent for results reported for CIN3+ cases.

In women who were high-risk HPV-positive, the specificity of HPV combined with TruScreen was 50% (HPV + TCT 39.9%) the sensitivity for HPV and TruScreen combined was 93.94% (HPV + TCT 87.88%).

The study concluded that TruScreen has the potential for screening high-grade cervical precancerous lesions and may replace cytological tests as a cervical cancer screening method in China. TruScreen minimises the inherit subjectivity of interpretation of cytological tests and the dependency on pathology infrastructure.

TruScreen CEO Juliet Hull said: “It is pleasing to see an ever-increasing number of published studies coming through that highlight the effectiveness of the TruScreen screening device in detecting cervical cancer. It adds to the body of evidence already available, with a substantial amount of the publishes studies undertaken in China, our major offshore market. But the full set of advantages the TruScreen screening device provides to both patients and clinics do not get reflected in these studies. When measured against other screening options, our device is non-invasive, affordable, quick, easy to learn and independent from laboratory infrastructure, making it a cost-effective alternative to expensive cytology methods. At the same time, we remain intent on building on these existing competitive advantages. We are now in the process of releasing a Firmware update to TruScreen devices already in the market, which enhances their data security and more effectively interfaces with compatible hospitals’ systems. This determination to continually evolve our unique product offering bodes well for TruScreen’s growth potential over coming years.”


This announcement was approved for release by the Board.

For more information, visit or contact:
Juliet Hull
Chief Executive Officer

Guy Robertson
Chief Financial Officer

Investor Relations
Julia Maguire
The Capital Network
+ 61 2 8999 3699

Announcement PDF

Markets News

Markets market close
NZ sharemarket rebounds with Wall Street rally
Dan Brunskill | Mon, 27 Jun 2022

US markets rallied on Friday night as traders began thinking an economic slowdown would stop the US Federal Reserve from hiking interest rates.

News in Brief FREE
Cannasouth announces new manufacturing deal
Staff reporters | Mon, 27 Jun 2022

The medicinal cannabis company has signed a three-year deal with Harker Herbal Products.

Fletcher wowed analysts at last week’s investor day
Jenny Ruth | Mon, 27 Jun 2022

All five of the analysts’ reports BusinessDesk has seen have either “overweight” or “outperform” investment recommendations on Fletcher shares.

How to survive a bear market
Dan Brunskill | Fri, 24 Jun 2022

Bear markets can be stressful but they also present opportunities for investors, says Salt Funds' Greg Fleming.  

Markets FREE
Index heavyweights pull NZ shares higher
Ella Somers | Thu, 23 Jun 2022

Peter McIntyre, an investment adviser at Craigs Investment Partners, said it had been a “strong performance” in today’s market.

How we can fix New Zealand's ports – Don Braid
Brent Melville | Thu, 23 Jun 2022

The head of the multinational logistics group says having container cranes sitting idle across the country is a waste of assets

Markets Exclusive
Investment platform Stake brings stock lending to NZ
Dan Brunskill | Thu, 23 Jun 2022

The zero-brokerage fee share trading platform is looking for ways to bring in revenue and make its business model more sustainable. 

Fletcher to deliver at least $850m operating earnings in 2023
Jenny Ruth | Thu, 23 Jun 2022

Fletcher Building achieved second-half profit margins of 9.5%, just below its target of 10% by the 2023 financial year.

Markets market close
NZ shares fall as Eroad near all-time low
Dan Brunskill | Wed, 22 Jun 2022

Eroad had a second day as the index’s biggest decliner, falling more than 5% to $1.57 and bringing its decline over the past year to almost 75%.

Fletcher said Gib orders reached double capacity
Staff reporters | Wed, 22 Jun 2022

Fletcher's new plant at Tauriko, due to open next year, will increase industry capacity by 30%.

Craigs recommends investors be ‘overweight’ Fletcher shares
Jenny Ruth | Wed, 22 Jun 2022

Even under a “bear-case scenario”, the house building pipeline should support Fletcher’s medium-to-long-term performance.

Markets FREE
NZ shares rise as recession fears ease
Ella Somers | Tue, 21 Jun 2022

Some investors in NZ’s market took the opportunity to buy up “beaten up” stock on the index today, Devon Funds' Greg Smith said.

Markets market close
NZ shares flat as recession risk puts investors off trading
Dan Brunskill | Mon, 20 Jun 2022

Trading volumes were unusually light, with US markets closed tonight for a national holiday.

NZSA, Simplicity call for Fletcher chair Bruce Hassall to resign
Jenny Ruth | Mon, 20 Jun 2022

The shareholder representatives say the Fletcher board must bear ultimate responsibility for the company’s poor performance and the Gib plasterboard shortage.

NZME makes up for slow buyback with $10m special dividend
Dan Brunskill | Mon, 20 Jun 2022

NZME has only spent $5.3m of the $30m set aside for share buybacks. 

Macquarie says Australian banks are profiting from low term deposit rates
Dan Brunskill | Mon, 20 Jun 2022

Are banks being too slow to raise term deposit rates? Some analysts say yes. 

Markets Market Close
Cautious trading follows week of share market turmoil
Ella Somers | Fri, 17 Jun 2022

Peter McIntyre, an investment adviser at Craigs Investment Partners, says New Zealand’s market has been "reliably well-behaved over the course of the day".

Fabrum open to listing to keep up with hydrogen demand
Brent Melville | Fri, 17 Jun 2022

The firm has doubled its headcount and is looking to raise capital to expand its manufacturing and engineering focus into green hydrogen applications.

Australia's electricity train wreck has lessons for NZ
Ian Llewellyn | Fri, 17 Jun 2022

Meridian says the fact that Australia's electricity market has turned into a train wreck shows its decision to pull out was the right one.

Primary Sector
Government favours Fonterra’s commercial interests: MPI
Jenny Ruth | Fri, 17 Jun 2022

The Ministry for Primary Industries estimated Fonterra’s restructuring would cost the average farmer between $135,000 and $400,000.

HW Richardson takes 'uncommercial' plunge into hydrogen
Brent Melville | Fri, 17 Jun 2022

New Zealand's biggest transport operator plans to have its first 10 dual-fuel hydrogen trucks on the road next year. 

Markets market close
NZ share market climbs as US Federal Reserve hikes interest rates
Dan Brunskill | Thu, 16 Jun 2022

Oanda market analyst Edward Moya said the absence of a Bitcoin rally could be a troubling sign for some investors.

Wounded Sky under pressure to return cash after MediaWorks U-turn
Daniel Dunkley | Thu, 16 Jun 2022

Sky TV and MediaWorks will be brushing themselves off after a bruising response to their proposal scotched a SkyWorks deal.

Sky pulls out of MediaWorks takeover
Daniel Dunkley | Thu, 16 Jun 2022

Sky TV has backed away from a dalliance with radio and outdoor advertising.